Literature DB >> 12111693

Expression of urocortin mRNA and peptide in the human prostate and in prostatic adenocarcinoma.

Felice Arcuri1, Marcella Cintorino, Pasquale Florio, Federica Floccari, Loreta Pergola, Roberta Romagnoli, Felice Petraglia, Piero Tosi, Maria Teresa Del Vecchio.   

Abstract

BACKGROUND: Urocortin (UCN) is a recently described neuropeptide member of the CRF family, responsible for the secretion of the proopiomelanocortin-derived peptides from the pituitary gland. Although previous results have demonstrated the synthesis of several neuroendocrine factors in the prostate, no studies have been carried out on the expression of UCN in the human gland.
METHODS: UCN expression was evaluated in benign prostatic hyperplasia and prostatic tumor tissues by RT-PCR and immunohistochemistry.
RESULTS: UCN mRNA and peptide were demonstrated in all specimens tested. In nonneoplastic tissues, UCN was localized in the secretory luminal epithelial and basal layer cells, in the smooth muscle component of the stroma, and in lymphoid infiltrates. An intense immunostaining was evident in prostate adenocarcinoma cells.
CONCLUSIONS: The results of the present study demonstrate for the first time UCN expression in the human prostate and in prostate cancer, and suggest a potential involvement of UCN in prostate physiopathology. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111693     DOI: 10.1002/pros.10094

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

Review 1.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

2.  Urocortin 1 modulates immunosignaling in a rat model of colitis via corticotropin-releasing factor receptor 2.

Authors:  Jen Chang; Melanie R Adams; Matthew S Clifton; Min Liao; Julia H Brooks; Burcu Hasdemir; Aditi Bhargava
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-02-17       Impact factor: 4.052

3.  [Expression of corticotropin releasing factor receptor 2 (CRFR2) in the human prostate. A new potential target for medical therapy of benign prostatic hyperplasia].

Authors:  H Tezval; A S Merseburger; M Seidler; J Serth; M A Kuczyk; M Oelke
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

Review 4.  Urocortin and the brain.

Authors:  Weihong Pan; Abba J Kastin
Journal:  Prog Neurobiol       Date:  2007-11-07       Impact factor: 11.685

5.  An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population.

Authors:  Xing Gu; Peng Qi; Feiguo Zhou; Qiang Ji; Hao Wang; Tonghai Dou; Yunpeng Zhao; Chunfang Gao
Journal:  Hum Genet       Date:  2009-10-08       Impact factor: 4.132

6.  Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation.

Authors:  Hossein Tezval; Stefanie Jurk; Farahnaz Atschekzei; Jan U Becker; Olaf Jahn; Jürgen Serth; Markus A Kuczyk
Journal:  World J Urol       Date:  2009-12       Impact factor: 4.226

7.  CRF2 signaling is a novel regulator of cellular adhesion and migration in colorectal cancer cells.

Authors:  Benjamin Ducarouge; Marjolaine Pelissier-Rota; Michèle Lainé; Nadine Cristina; Yvan Vachez; Jean-Yves Scoazec; Bruno Bonaz; Muriel Jacquier-Sarlin
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

Review 8.  Urocortins in the mammalian endocrine system.

Authors:  Caterina Squillacioti; Alessandra Pelagalli; Giovanna Liguori; Nicola Mirabella
Journal:  Acta Vet Scand       Date:  2019-10-04       Impact factor: 1.695

9.  Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis.

Authors:  Yo-Liang Lai; Chia-Hsin Liu; Shu-Chi Wang; Shu-Pin Huang; Yi-Chun Cho; Bo-Ying Bao; Chia-Cheng Su; Hsin-Chih Yeh; Cheng-Hsueh Lee; Pai-Chi Teng; Chih-Pin Chuu; Deng-Neng Chen; Chia-Yang Li; Wei-Chung Cheng
Journal:  Cancers (Basel)       Date:  2022-03-19       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.